# PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

> **NCT05465941** · PHASE2 · RECRUITING · sponsor: **Mayo Clinic** · enrollment: 43 (estimated)

## Conditions studied

- Platinum-Resistant Fallopian Tube Carcinoma
- Platinum-Resistant Ovarian Carcinoma
- Platinum-Resistant Primary Peritoneal Carcinoma
- Stage IV Fallopian Tube Cancer AJCC v8
- Stage IV Ovarian Cancer AJCC v8
- Stage IV Primary Peritoneal Cancer AJCC v8

## Interventions

- **PROCEDURE:** Biopsy
- **DRUG:** Pegylated SN-38 Conjugate PLX038
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Biospecimen Collection

## Key facts

- **NCT ID:** NCT05465941
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-09-14
- **Primary completion:** 2027-02-15
- **Final completion:** 2031-12-31
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2026-02-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05465941

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05465941, "PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05465941. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*